We recently compiled a list of the 10 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where REGENXBIO Inc. (NASDAQ:RGNX) stands against the other stocks on Jim Cramer's radar.

Jim Cramer, the host of Mad Money, addressed some of Wall Street's primary concerns on Tuesday, offering insights into how the White House may interpret the ongoing issues surrounding President Donald Trump’s aggressive tariff policies. As alarmed investors continue to react to the potential consequences of these actions, Cramer outlined the main observations that point to the administration's unpredictable approach. First, Cramer emphasized that the White House is less concerned about whether a country is an ally and more focused on whether that nation is paying its fair share.

“What matters to the White House is not whether a country is an ally. It's whether that country pays its freight. Its approach is very uneven, which makes it very difficult to fathom.”

READ ALSO Jim Cramer and Analysts Like These 10 Stocks and Jim Cramer Discussed These 7 Stocks

Moving on, Cramer highlighted the apparent disregard the White House has for preexisting trade agreements. Even if a deal was negotiated during Trump’s first term or involved allies, it seems irrelevant to the current administration’s priorities. Cramer noted that the White House's stance is driven by a belief that trade agreements should not result in the loss of American jobs, regardless of previous negotiations.

Cramer then pointed out the inconsistency in tariff changes. He mentioned that American companies relying on labor from Mexico and Canada could face significant costs, while companies from countries like South Korea, Japan, and various European nations enjoy minimal tariffs on the millions of cars they ship to the U.S. He remarked that fairness does not appear to be a main consideration in these decisions. Next, Cramer touched on Taiwan's situation and said:

“Taiwan may or may not be relevant. It, it could help its cause if it started paying more for its defense. It doesn't matter that Taiwan Semi’s located there and is the most, single most important strategic asset in the world for both our industry and our military.”

Cramer also pointed out that there is still no clear timeline for when the tariffs imposed on Mexico will be paid. In another remark, Cramer discussed the uncertainty of whether the White House will offer some form of rebate to American companies that commit to expanding jobs and factories within the U.S. Addressing the broader picture, Cramer emphasized that the concerns of U.S. allies or investors seem to have little influence on the White House's approach.

“It makes no difference what our allies say or do. Their assurances mean nothing. If you're upset and sell stocks because of them, or if you bought stocks while Biden was president, or even a few months ago when you could convince yourself that Trump wouldn't go crazy with the tariffs, well, that doesn't matter as the White House sees it.”

According to Cramer, the current administration’s priorities are focused on advancing American dominance, not responding to investor or international concerns. He concluded by highlighting the administration's disbelief that investors continue to voice complaints over the administration's actions.

Our Methodology

For this article, we compiled a list of 10 stocks that were discussed by Jim Cramer during the episode of Mad Money aired on March 4. We listed the stocks in ascending order of their hedge fund sentiment as of the fourth quarter of 2024, which was taken from Insider Monkey’s database of over 1,000 hedge funds.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

A scientist in a lab coat observing a microscope in a sterile environment, symbolizing the progress of gene therapy.

REGENXBIO Inc. (NASDAQ:RGNX)

Number of Hedge Fund Holders: 35

During the lightning round, a caller asked if they should buy, sell, or hold REGENXBIO Inc. (NASDAQ:RGNX). Here’s what Mad Money’s host had to say:

“This thing just does nothing but go down, and it loses a ton of money. I can't possibly recommend putting any money into that thing.”

REGENXBIO Inc. (NASDAQ:RGNX) is a clinical-stage biotechnology company focused on developing gene therapies using its proprietary NAV Technology Platform, with a pipeline that includes treatments for various genetic disorders. In 2024, Cramer commented:

“You have this REGENXBIO, which is a drug company which revealed that it might have something against Duchenne muscular dystrophy. That's a terrible disease, very rare meaning they can charge very high prices for any treatment. That stock folded nearly 25% over two days in response to the news.”

For context, since the comment was made on February 8, 2024, REGENXBIO (NASDAQ:RGNX) stock went down more than 62%.

Overall RGNX ranks 8th on our list of the stocks on Jim Cramer's radar. While we acknowledge the potential of RGNX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than RGNX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

 

READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap

 

Disclosure: None. This article is originally published at Insider Monkey.